KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Capital Expenditures (2020 - 2025)

AbCellera Biologics (ABCL) has disclosed Capital Expenditures for 6 consecutive years, with $9.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Capital Expenditures fell 37.02% year-over-year to $9.8 million, compared with a TTM value of $42.8 million through Dec 2025, down 45.44%, and an annual FY2025 reading of $42.8 million, down 45.44% over the prior year.
  • Capital Expenditures was $9.8 million for Q4 2025 at AbCellera Biologics, up from $8.9 million in the prior quarter.
  • Across five years, Capital Expenditures topped out at $36.8 million in Q2 2021 and bottomed at $3.6 million in Q1 2021.
  • Average Capital Expenditures over 5 years is $16.4 million, with a median of $14.5 million recorded in 2022.
  • The sharpest move saw Capital Expenditures surged 893.9% in 2021, then tumbled 55.94% in 2025.
  • Year by year, Capital Expenditures stood at $9.4 million in 2021, then soared by 30.75% to $12.3 million in 2022, then increased by 17.04% to $14.4 million in 2023, then increased by 8.31% to $15.6 million in 2024, then plummeted by 37.02% to $9.8 million in 2025.
  • Business Quant data shows Capital Expenditures for ABCL at $9.8 million in Q4 2025, $8.9 million in Q3 2025, and $13.4 million in Q2 2025.